Alkermes Sees Payer Savings Opportunity With Aristada Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting injectable aripiprazole lauroxil cleared six weeks late, but Alkermes is happy with label's flexibility on dosing, saying product will be differentiated from Abilify Maintena.
You may also be interested in...
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.